Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Status:
Terminated
Trial end date:
2011-04-26
Target enrollment:
Participant gender:
Summary
This study tests the hypothesis that a purely immunosuppressive preparative regimen allows
engraftment of related or unrelated allogeneic hematopoietic stem cells in subjects with
high-risk malignancies, without causing the post-transplant myelosuppression (e.g.,
neutropenia, thrombocytopenia) that occurs with currently used reduced-intensity
(nonmyeloablative) preparative regimens. This study incorporates both safety and efficacy
endpoints and evaluates a novel preparative regimen of alemtuzumab plus continuous-infusion
pentostatin, two immunosuppressive agents with different mechanisms of action, in recipients
of related or unrelated allogeneic hematopoietic stem cell transplantation.